Objectives: Chronic pulmonary infection by Pseudomonas aeruginosa in cystic fibrosis patients is virtually impossible to eradicate by means of existing free antibiotics. We sought to assess the antibacterial activities of liposomal gentamicin against clinical isolates of P. aeruginosa.
Introduction
Pseudomonas aeruginosa is a major cause of nosocomial infections and accounts for $ 95% of deaths in the cystic fibrosis population. 1 A major reason for its prominence as a pathogen is its high intrinsic resistance to most available antibiotics. 2 A drug-delivery system that could reduce antibiotic toxicity while increasing the therapeutic indices is of great interest, and liposome-encapsulated antimicrobial agents can provide these benefits.
The present study was undertaken to evaluate encapsulation efficiency, in vitro stability and antibacterial activity of our newly developed liposomal gentamicin formulations against resistant strains of P. aeruginosa.
Materials and methods
We encapsulated gentamicin into liposomes with different lipid compositions [1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)] and cholesterol in the molar ratio of 2:1 by a sonication method, as previously described. 3 The average particle size and the polydispersity index 4 were determined by laser light scattering with the use of a NICOMP 270/autodilute Submicron Particle Sizer (Santa Barbara, CA, USA JAC the content of total lipid. The concentration of gentamicin incorporated into liposomes was measured by agar diffusion assay, using a laboratory strain of Staphylococcus aureus (ATCC 29213) as an indicator organism. 5 The in vitro stability of liposome-encapsulated gentamicin was determined in PBS, pH 7.2 or in normal human pooled plasma at 4 or 378C with mild agitation. After incubation periods of 0.25, 0.5, 1, 3, 6, 12, 24 and 48 h, samples were removed and centrifuged (18300 g for 15 min at 48C) to remove the liposomal gentamicin. The free gentamicin concentrations in the supernatants were determined by agar diffusion assay. 5 Antibiotic release was expressed as a percentage of liposomal retention of the initially encapsulated gentamicin.
We studied the antibacterial effect of these formulations on non-mucoid (PA-1, PA-48912 -2 and M-57192R) and mucoid (PA-48912-1, PA-48913 and M-26250) strains of P. aeruginosa isolated from sputum of pulmonary infected cystic fibrosis patients at the Memorial Hospital (Sudbury, ON, Canada). Laboratory strains of S. aureus (ATCC 29213) and P. aeruginosa (ATCC 27853) were used as test organisms as well as reference strains for quality control. The MICs of free and liposomal gentamicin for clinical isolates of P. aeruginosa were determined as previously described. 5 The data are expressed as means ± S.E.M. of three independent experiments. Comparisons were made by paired Student's t-test and P < _ 0.05 was considered significant. For multiple comparisons within and between groups, ANOVA with the two-tailed Dunnett's post-test analysis was used.
Results
The average diameter of liposome-encapsulated gentamicin with different lipid compositions varied from 408 ± 28 to 418 ± 21 nm, with no significant difference between various liposomal preparations. The polydispersity index [the measurement of homogeneity of dispersion, ranging from 0.0 (homogeneous) to 1.0 (heterogeneous)] for the size distribution of liposomal formulations ranged from 0.59 ± 0.009 to 0.74 ± 0.007. Encapsulation efficiencies of gentamicin in all three types of liposomes were 4%-5.18% of the initial amount of the drug in solution. The loading capacity of gentamicin, however, was formuladependent and varied significantly (P < 0.001) from 26.7 ± 1.3 to 34.5 ± 1.5 mg/mmol.
All liposomal preparations retained >70% of the initially encapsulated gentamicin up to 48 h in PBS. Generally, however, liposomes incubated at 48C retained more antibiotic than those incubated at 378C. For instance, the liposomes composed of DPPC-CHOL (DPPC-cholesterol) retained significantly more antibiotic at 48C than those stored at 378C (89.3% ± 1.3% versus 80.6% ± 1.2%, P < 0.0001) at the end of a 48 h experimental period. We also compared the drug release profile of different liposomal formulations and found that the liposomes composed of DPPC-CHOL retained more antibiotic than that of DMPC-CHOL at 48C (89.3% ± 1.3% versus 77.3% ± 1.1%, P < 0.0003) in 48 h. Likewise, the liposomes composed of DPPC-CHOL Figure 1 . Gentamicin retention in liposomes of various lipid compositions in human plasma. Liposome-encapsulated gentamicin composed of DMPC-CHOL (filled circles), DPPC-CHOL (filled triangles), DSPC-CHOL (filled squares) were incubated at 378C in normal human pooled plasma with mild agitation. At the times indicated, plasma samples were removed (centrifugation at 18300 g for 15 min at 48C) and gentamicin concentrations in the supernatants were determined by agar diffusion microbiological assay. Results are means±S.E.M. of three separate experiments. All formulations retained a comparable amount of gentamicin at the end of a 48 h assay period. a Two-fold dilution series of free and liposomal gentamicin were prepared in triplicate in a broth medium and mixed with 100 mL of P. aeruginosa (1.5Â10 7 cfu/mL). The test tubes were then incubated at 378C for 24 h in a shaking water bath. The MICs were determined as the lowest concentration of the antibiotics that inhibited visible bacterial growth. Two control strains, P. aeruginosa (ATCC 27853) and S. aureus (ATCC 29213), were used to validate this method. Two separate experiments were performed and no significant differences in the MIC values were observed. retained more antibiotic than that of DSPC-CHOL (89.3% ± 1.3% versus 84.1% ± 1.2%, P < 0.005) at the end of a 48 h experimental period. However, the drug-release data obtained at 378C did not indicate any significant difference in the lipid compositions.
To mimic physiological conditions, we determined the drugrelease kinetics of liposomal gentamicin incubated in normal human pooled plasma at 378C (Figure 1 ). All liposomal formulations released $ 40% of the encapsulated drug in 48 h. Although we did not detect a significant difference in the release kinetics of gentamicin in plasma in relation to different liposomal formulations, we found that the liposomes incubated in PBS at 378C retained significantly more antibiotic than when they were incubated in plasma over a period of 48 h. For instance, the liposomes composed of DPPC-CHOL retained 80.6% ± 1.2% of initially encapsulated drug at 378C in PBS, compared with 64.1% ± 4.3% (P < 0.0001) of the same formulation in plasma.
The MICs of all three liposomal gentamicin formulations for two highly gentamicin-resistant mucoid and non-mucoid clinical strains of P. aeruginosa were significantly lower than the MICs (Table 1 ) of free gentamicin (1 -2 versus 256-512 mg/L). Similarly, the MICs of the liposomal gentamicins for low or moderate gentamicin-resistant strains were at least one-half of the MICs of free gentamicin for the same organisms (P < _ 0.05). Overall, no significant difference was observed in the activities of liposomal gentamicin formulations due to their lipid composition. Liposomes containing PBS or a combination of empty liposomes with free drug had no additive effect on gentamicin's antibacterial activity. 6 
Discussion
The encapsulation efficiency of our liposomal formulations (4% -5%) is higher than the values reported by some investigators, such as Lutwyche et al., 7 who reported an encapsulation efficiency of <3% for a liposomal gentamicin composed of DPPC-CHOL (55:45, molar ratio). However, higher encapsulation efficiencies have been reported by other researchers. 8 Liposomes have a low melting temperature (37.58C) due to the lack of cholesterol and they begin to destabilize at 338C. Therefore, we chose to incorporate cholesterol in our formulations in order to enhance the stability of our liposomes.
Our drug-release data reported here clearly indicate a significant improvement in gentamicin retention by our formulations, regardless of the temperature. The contributing factors include our choice of lipids, the ratio of lipid to cholesterol (2:1, molar ratio) and the chemical nature of the antibiotic, gentamicin. We found that liposomes composed of DPPC-CHOL retained more antibiotic in PBS at 48C than liposomes composed of DSPC-CHOL or DMPC-CHOL. Although at present we do not know why the DPPC-CHOL formula increases the stability of these liposomes in PBS, other studies echo similar findings. It has been reported that the DPPC-encapsulated paclitaxel, an antitumour agent, is more stable in PBS than the liposomes composed of DMPC or DSPC. 9 These authors argued that paclitaxel incorporation increases the phase-transition temperature of the lipid vesicles and that this broadening effect was greatest for DPPC, hence leading to a more stable compound. Although our formulations incubated in normal human pooled plasma released 20% more antibiotic than those incubated in PBS at 378C, they performed well when compared with liposomes composed of egg phosphatidylcholine. 10 All clinical strains of P. aeruginosa used in this study are considered resistant (NCCLS) to gentamicin (MIC > _ 16 mg/L). Our formulations, however, significantly enhanced the susceptibilities of these organisms to gentamicin, from highly resistant to either intermediate (MIC < _ 8 mg/L) or susceptible (MIC < _ 4 mg/L) to this antimicrobial agent. Liposomes may protect the encapsulated drug from the action of bacterial enzymes as well as facilitating its diffusion across the bacterial envelope. To the best of our knowledge, however, this is the first report on liposomal formulations that enhance gentamicin antibacterial activity against gentamicin-resistant clinical strains of P. aeruginosa. We are investigating the mechanism by which these formulations enhance gentamicin activity against the resistant strains of P. aeruginosa.
